Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.
Overview
The market for weight loss drugs continues to move fast, and one of the main arenas for competition right now is how those medicines are formulated. For a lot of people, taking a daily pill is less burdensome than taking a once-a-week injection, which is why drug developers are working on porting their injectables over to the oral route.
Viking Therapeutics (NASDAQ: VKTX) doesn't yet have approval for its injectable candidate, VK2735, but it does have decent data, which is why its oral formulation of the same molecule is about to enter late-stage testing. Given this setup, is now a good time to buy Viking's stock?
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.